Company acquires 70,000 square foot distribution facility from Novartis. The facility, located in Buffalo Grove, Ill., will begin operations May 1 and will distribute Roberts' entire U.S. product line, including the orthostatic hypotension treatment, ProAmatine (midodrine), and the essential thrombocythemia treatment, Agrylin (anagrelide). Roberts purchased a manufacturing facility in Canada from Searle in July that is currently packaging OTC products. Prescription products will be phased in over the next year and a half, the company says...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth